Angiotensin Receptor Antagonists
"Angiotensin Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR.
| Descriptor ID |
D057911
|
| MeSH Number(s) |
D27.505.519.162
|
| Concept/Terms |
Angiotensin Receptor Antagonists- Angiotensin Receptor Antagonists
- Antagonists, Angiotensin Receptor
- Receptor Antagonists, Angiotensin
- Angiotensin Receptor Blockers
- Receptor Blockers, Angiotensin
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin Receptor Antagonists".
This graph shows the total number of publications written about "Angiotensin Receptor Antagonists" by people in this website by year, and whether "Angiotensin Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 2 | 2 |
| 2003 | 1 | 1 | 2 |
| 2005 | 0 | 1 | 1 |
| 2007 | 4 | 0 | 4 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 4 | 1 | 5 |
| 2012 | 2 | 0 | 2 |
| 2013 | 2 | 3 | 5 |
| 2014 | 3 | 2 | 5 |
| 2015 | 2 | 2 | 4 |
| 2016 | 3 | 3 | 6 |
| 2017 | 2 | 3 | 5 |
| 2018 | 3 | 1 | 4 |
| 2019 | 3 | 4 | 7 |
| 2020 | 4 | 4 | 8 |
| 2021 | 1 | 7 | 8 |
| 2022 | 1 | 7 | 8 |
| 2023 | 1 | 8 | 9 |
| 2024 | 3 | 4 | 7 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiotensin Receptor Antagonists" by people in Profiles.
-
Group-based trajectory modeling to identify longitudinal patterns and predictors of adherence among older adults on concomitant triple therapy (oral antidiabetic, renin-angiotensin-system antagonists, statins). J Manag Care Spec Pharm. 2025 Apr; 31(4):396-405.
-
Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalemia or High Risk of Hyperkalemia: Rationale and Design of the CARE-HK in HF Registry. J Card Fail. 2025 Jun; 31(6):881-891.
-
Indian Consensus on the Role and Position of Angiotensin Receptor-neprilysin Inhibitors in the Management of Heart Failure. J Assoc Physicians India. 2024 Sep; 72(9):75-82.
-
Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure. Am J Cardiovasc Drugs. 2024 Jul; 24(4):481-504.
-
Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes. JAMA Netw Open. 2024 06 03; 7(6):e2418808.
-
The national financial burden of guideline directed medical therapy for heart failure patients from 2013 to 2021. Curr Probl Cardiol. 2024 Aug; 49(8):102684.
-
Consensus Statement from India on the Renal Benefits of ARNi, SGLT-2i, and Bisoprolol in Chronic Kidney Disease. J Assoc Physicians India. 2024 May; 72(5):77-88.
-
Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2024 04 29; 4:CD006257.
-
Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies. Trials. 2024 Mar 21; 25(1):203.
-
Factors associated with longer survival among older medicare patients after diagnosis of supratentorial primary brain malignancies: a retrospective cohort study. Neurol Res. 2024 May; 46(5):379-390.